{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=44", "query": { "intervention": "liposomal doxorubicin", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 1375, "total_pages": 138, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=45&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=43&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T16:45:57.660Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07504588", "title": "Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma", "Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma", "Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma", "Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "Anti-VEGF Monoclonal Antibody", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Sacituzumab Govitecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 87, "start_date": "2026-09-24", "completion_date": "2029-04-12", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-17T16:45:57.660Z", "location_count": 10, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 7 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Post Falls", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT07504588" }, { "nct_id": "NCT00524316", "title": "Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "sunitinib malate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "hepatic artery embolization", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 16, "start_date": "2007-04", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-17T16:45:57.660Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524316" }, { "nct_id": "NCT06422806", "title": "Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Dedifferentiated Liposarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Unresectable Dedifferentiated Liposarcoma", "Unresectable Undifferentiated Pleomorphic Sarcoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging Testing", "type": "PROCEDURE" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 365, "start_date": "2024-09-11", "completion_date": "2032-04-18", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-17T16:45:57.660Z", "location_count": 255, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Dublin, California + 207 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06422806" }, { "nct_id": "NCT04517435", "title": "ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "ME-401", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deepa Jagadeesh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-04-28", "completion_date": "2023-05-17", "has_results": true, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-10-17T16:45:57.660Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04517435" }, { "nct_id": "NCT05261490", "title": "Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Fallopian Tube Cancer", "Epithelial Ovarian Cancer", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "maplirpacept (PF-07901801)", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin (PLD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2022-08-01", "completion_date": "2024-02-15", "has_results": true, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-10-17T16:45:57.660Z", "location_count": 18, "location_summary": "Santa Monica, California • Miami, Florida • Orlando, Florida + 10 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05261490" }, { "nct_id": "NCT00074490", "title": "Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Leukemia", "Myeloproliferative Disorders", "Multiple Myleoma", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Peripheral blood stem cell (PBSC) transplantation", "type": "PROCEDURE" }, { "name": "T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells", "type": "GENETIC" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Allogeneic hematopoietic stem cell transplant (HSCT)", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "T-Rapa cell Donor Lymphocyte Infusion (DLI)", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "GENETIC" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "11 Years to 90 Years" }, "enrollment_count": 442, "start_date": "2004-01-01", "completion_date": "2017-08-16", "has_results": true, "last_update_posted_date": "2018-12-31", "last_synced_at": "2026-10-17T16:45:57.660Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Hackensack, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074490" }, { "nct_id": "NCT00581360", "title": "Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenoid Cystic Carcinoma" ], "interventions": [ { "name": "doxorubicin and bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2007-11", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2016-11-07", "last_synced_at": "2026-10-17T16:45:57.660Z", "location_count": 21, "location_summary": "Steubenville, Ohio • Beaver, Pennsylvania • Clairton, Pennsylvania + 12 more", "locations": [ { "city": "Steubenville", "state": "Ohio" }, { "city": "Beaver", "state": "Pennsylvania" }, { "city": "Clairton", "state": "Pennsylvania" }, { "city": "Greensburg", "state": "Pennsylvania" }, { "city": "Greensburg", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00581360" }, { "nct_id": "NCT00003776", "title": "Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "trimetrexate glucuronate", "type": "DRUG" }, { "name": "surgical procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": null, "start_date": "1998-12", "completion_date": "2000-03", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-10-17T16:45:57.660Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003776" }, { "nct_id": "NCT01539174", "title": "Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2016-03-03", "last_synced_at": "2026-10-17T16:45:57.660Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01539174" }, { "nct_id": "NCT04388839", "title": "Evolutionary Therapy for Rhabdomyosarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rhabdomyosarcoma" ], "interventions": [ { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Actinomycin D", "type": "DRUG" }, { "name": "Cyclophosphamide Pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 12, "start_date": "2020-12-29", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-10-17T16:45:57.660Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04388839" } ] }